Dianthus Therapeutics (DNTH) Other financing activities (2018 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Other financing activities of $271.7 million for Q3 2025, up 91680.07% year-over-year from N/an in Q3 2024, and up 47729.05% quarter-over-quarter from $568000.0 in Q2 2025.
Dianthus Therapeutics (DNTH) Other financing activities (2018 - 2025) Analysis & Trends
Dianthus Therapeutics' Other financing activities history runs 8 years deep, the most recent figure standing at $271.7 million for Q3 2025.
- In Q3 2025, Other financing activities rose 91680.07% year-over-year to $271.7 million; the TTM figure through Sep 2025 stood at $272.7 million (up 44320.85% YoY), while the FY2024 annual figure was $1.1 million, up 21700.0% from the prior year.
- Other financing activities for Q3 2025 stood at $271.7 million, up from $568000.0 in the prior quarter.
- The five-year high for Other financing activities was $271.7 million in Q3 2025, with the low at -$49000.0 in Q3 2022.
- The 5-year median for Other financing activities is $296000.0 (2024), against an average of $32.7 million.
- Peak annual rise in Other financing activities reached 91680.07% in 2025, while the deepest fall reached 88.56% in 2025.
- Dianthus Therapeutics' Other financing activities stood at $86.0 million in 2021, then slumped by 100.06% to -$49000.0 in 2022, then surged by 110.2% to $5000.0 in 2023, then surged by 9420.0% to $476000.0 in 2024, then jumped by 56973.32% to $271.7 million in 2025.
- Business Quant data shows DNTH's Other financing activities at $271.7 million in Q3 2025, $568000.0 in Q2 2025, and $31000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 271.67 Mn |
| Sep 30, 2025 | 271.67 Mn |
| Jun 30, 2025 | 568,000.00 |
| Jun 30, 2025 | 568,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | 476,000.00 |
| Dec 31, 2024 | 476,000.00 |
| Sep 30, 2024 | 296,000.00 |
| Sep 30, 2024 | 296,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Mar 31, 2024 | 271,000.00 |
| Mar 31, 2024 | 271,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Sep 30, 2022 | -49,000.00 |
| Sep 30, 2022 | -49,000.00 |
| Jun 30, 2021 | 85.98 Mn |
| Jun 30, 2021 | 85.98 Mn |